Epigral growth ratios

·ChemicalsChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−0.9%+32.2%−11.8%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−20.2%+47.7%−30.2%
−31.0%+61.7%−38.3%
−7.2%+82.7%−44.6%
−9.1%+79.7%−44.6%
+11.2%+12.8%+14.9%
+16.6%+51.9%+17.3%
−1.1%+10.8%−36.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

EPIGRAL₹900.00

Epigral Limited

· Chemicals
₹ CrorePeersYASHOGUJALKALIFCLFOSECOINDVISHNUTATVAGALAXYSURFJUBLCPLMcap ₹3,883 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-11.8+32.2-0.9—
EBITDA Growth—-30.2+47.7-20.2—
EBIT Growth—-38.3+61.7-31.0—
Net Income Growth—-44.6+82.7-7.2—
EPS Growth—-44.6+79.7-9.1—
Total Assets Growth—+14.9+12.8+11.2—
Total Equity Growth—+17.3+51.9+16.6—
Cash from Operations Growth—-36.5+10.8-1.1—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.